SINGULAR GENOMICS SYSTEMS INC. overview

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway at Beth Israel Deaconess...

SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P. On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common...

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC) (“Singular Genomics” or the “Company”), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per...

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024. “In the third quarter, we made significant progress in the development of the G4X spatial sequencer,” said Drew Spaventa, Chairman and Chief...

SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received an unsolicited non-binding proposal from Concentra Biosciences, LLC (“Concentra”) to acquire all of the Company’s outstanding shares of common stock for $12.00 per share in cash. As alternative consideration, Concentra stated...

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received a non-binding proposal from Deerfield Management Company, L.P. and certain affiliated funds (collectively, “Deerfield”), to acquire all of the Company’s outstanding shares of common stock that are not already owned by Deerfield...

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. “It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4...

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30...